Clinical trials: Relapsing-Remitting
Relapsing Remitting Multiple Sclerosis (RRMS)
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test (T100T), timed 25-foot walk test (T25FW), maximum walking distance (MWD), and Expanded Disability…
- Trial name
- TIMER (NCT00871780)
- Testing
- BG00002 (natalizumab)
- Where
- 15 sites in Belgium, Mexico and 4 more
- Volunteers
- 224 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment.
- Trial name
- NCT02212886
- Testing
- GA Depot 80 mg, GA Depot 40 mg
- Where
- 3 sites in Israel
- Volunteers
- 25 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis, Relapsing-Remitting
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
- Trial name
- NCT00228397
- Testing
- CCI-779
- Volunteers
- 221 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis, Relapsing Remitting
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01080053
- Where
- Argentina
- Volunteers
- 306 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587806
- Testing
- Autologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
- Where
- 2 sites in India, Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Relapsing-Remitting Multiple Sclerosis
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
This study is to find out if Interferon-beta (IFN-beta) can recover its effectiveness after a washout period in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta
- Trial name
- RENeu (NCT00493116)
- Testing
- Interferon-beta-1a, methylprednisolone
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT02019550
- Testing
- Rebif Rebidose, Rebiject II
- Where
- 21 sites in United States
- Volunteers
- 97 people
- Sponsor
- EMD Serono
Relapsing-Remitting Multiple Sclerosis, Fatigue
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
The primary objective of this trial is to observe the Multiple Sclerosis (MS) related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of…
- Trial name
- TYNERGY (NCT00884481)
- Testing
- Natalizumab
- Where
- 27 sites in Austria, Denmark and 2 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the…
- Trial name
- NCT04655222
- Testing
- Interferon Beta Therapy
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis
- Trial name
- NCT07006805
- Testing
- CABA-201
- Sponsor
- Cabaletta Bio
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Multiple Sclerosis
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1.
- Trial name
- NCT01031459
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046)
- Where
- 10 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Adherence Trial With MS LifeLines ® Services
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication…
- Trial name
- NCT01905527
- Testing
- Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) as their…
- Trial name
- IMPROVE (NCT02323269)
- Testing
- dimethyl fumarate
- Where
- 10 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203073
- Testing
- glatiramer acetate 20 mg, glatiramer acetate 20 mg, with mitoxantrone
- Volunteers
- 40 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-Remitting Multiple Sclerosis (RRMS)
Plegridy Satisfaction Study in Participants
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as…
- Trial name
- PLATINUM (NCT02587065)
- Testing
- peginterferon beta-1a
- Where
- 30 sites in Italy
- Volunteers
- 193 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Fingolimod -Response According to Coping - Evaluation
This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.
- Trial name
- GRACE (NCT01420055)
- Testing
- fingolimod
- Where
- 47 sites in France
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals